Physostigmine is superior to non-antidote therapy in the management of antimuscarinic delirium: a prospective study from a regional poison center.
Sean P BoleyTravis D OlivesStacey A BanghSamuel FahrnerJon B ColePublished in: Clinical toxicology (Philadelphia, Pa.) (2018)
This study provides further evidence of both the safety and efficacy of physostigmine in the treatment of antimuscarinic delirium.